Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jose Armonio

Internal Medicine Myrtle Beach, SC Medical Doctor

NPI 1528004413 CMS profile 250540

1301 48Th Avenue North, Suite B Southeast Medical Associates LLC, Myrtle Beach, SC 29577

Open in the dashboard

General payments

$4,061

224 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jose Armonio of Myrtle Beach, SC is reported in the CMS Open Payments database as having received $4,061 across 224 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $335 18
2024 General $556 20
2023 General $299 17
2022 General $479 27
2021 General $1,099 69
2020 General $853 49
2019 General $440 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Armonio
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jose Armonio were reported at $335. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jose Armonio Internal Medicine median Middle half National median
2019 $440 $159 $48–$570 $163
2020 $853 $119 $33–$402 $114
2021 $1,099 $135 $37–$521 $132
2022 $479 $141 $42–$496 $149
2023 $299 $149 $45–$519 $160
2024 $556 $154 $47–$537 $164
2025 $335 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $532 29 payments
  2. GlaxoSmithKline, LLC. $416 22 payments
  3. AstraZeneca Pharmaceuticals LP $406 19 payments
  4. Sanofi-Aventis U.S. LLC $353 21 payments
  5. Astellas Pharma US Inc $245 6 payments
  6. Lilly USA, LLC $221 13 payments
  7. Amarin Pharma Inc. $200 11 payments
  8. Kowa Pharmaceuticals America, Inc. $186 14 payments
  9. Novo Nordisk Inc $175 9 payments
  10. Pfizer Inc. $159 10 payments
  11. Other $1,169 70 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,798 219 payments
  2. Education $263 5 payments
Products named General payments · program years 2019–2025
  1. XARELTO $532 29 payments
  2. TRELEGY ELLIPTA $341 17 payments
  3. FARXIGA $320 13 payments
  4. Livalo $186 14 payments
  5. JARDIANCE $173 10 payments
  6. Vascepa $165 9 payments
  7. SOLIQUA 100/33 $160 8 payments
  8. ELIQUIS $140 9 payments
  9. Ozempic $136 7 payments
  10. Bystolic $134 10 payments
  11. Other $2,520 155 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 154 drugs

Part D claims

11,495

Median for Internal Medicine: 777

Drug cost

$1,186,636

Median for Internal Medicine: $73,373

Branded share of claims

21.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 246 $304,662
Ozempic Semaglutide Brand 80 $127,961
Januvia Sitagliptin Phosphate Brand 89 $94,477
Jardiance Empagliflozin Brand 72 $72,380
Farxiga Dapagliflozin Propanediol Brand 55 $63,016
Tradjenta Linagliptin Brand 49 $56,910
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 41 $38,411
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 31 $33,719
Entresto Sacubitril/Valsartan Brand 20 $28,420
Tresiba Flextouch U-100 Insulin Degludec Brand 13 $27,841

The 10 drugs with the highest cost, of 154 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$144,150

Of which drugs: $19

Medicare patients

408

Average age 77

Services billed

2,114

223 women, 185 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 41%
Ischemic heart disease 35%
COPD 32%
Atrial fibrillation 25%
Chronic kidney disease 25%
Heart failure 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ceftriaxone sodium, per 250 mg J0696 Office 11 52 $17
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 21 24 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $179
$179 55 —
Ozempic
  • Novo Nordisk Inc $46
$46 80 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $35
$35 — —
KRYSTEXXA
  • Amgen Inc. $28
$28 — —
NEXLETOL
  • Esperion Therapeutics, Inc. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

224 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record